Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh

Ivermectin study #45 of 113 Meta Analysis

12/11 Early treatment study

Hussain et al., International Journal of Molecular and Immuno Oncology, doi:10.25259/IJMIO_30_2020 (Preprint)
Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh

Source PDF Share Tweet

Small case study of ivermectin + doxycycline with 8 cancer patients, with all patients becoming PCR- by day 6 when tested again.

Hussain et al., 12/11/2020, preprint, 3 authors.

All 113 studies Meta Analysis

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit